Show Summary Details
Page of

Cancer chemoprevention 

Cancer chemoprevention
Cancer chemoprevention

Katja Zirlik

, Nadir Arber

, and Dirk Schrijvers



An analysis from the IBIS-I study (International Breast Cancer Intervention Study I) provides evidence for a long-term protective effect in breast cancer of tamoxifen.

However, overall breast cancer mortality has not been shown to decrease in chemoprevention trials by anti-hormones conducted so far.

Prophylactic use of aspirin has a favourable risk-to-benefit profile for colorectal cancer prevention in the average-risk general populations in the developed world.

Chemoprevention by hormone-interfering drugs like finasteride and dutasteride do not have a favourable risk-to-benefit profile in order to be proposed for chemoprevention of prostate cancer among healthy men.

Updated on 29 March 2019. The previous version of this content can be found here.
Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 24 August 2019

Cancer prevention certainly would be the best approach to cancer. Interventions should be effective, with minimal side effects, convenient, and inexpensive. Cancer chemoprevention is defined as the pharmacologic intervention with the process of carcinogenesis to prevent the development of overt malignant neoplasms in healthy individuals with elevated cancer risk. The present list of candidate cancer types for active chemoprevention is still short and includes SERMs (tamoxifen, raloxifene) and an aromatase-inhibitor (exemestane) for chemoprevention of breast cancers, showing significant reduction of cancer occurrence. The same holds true for reduction of the development of invasive cancers by aspirin, NSAIDs, and COX2-inhibitors in selected populations with increased colorectal cancer risk. There is also reduction of prostate cancers by long-term application of 5-alfa-reductase-inhibitors (finasteride, dutasteride) in selected high-risk populations. Many other potentially active anti-neoplastic compounds have been tested but do not meet all the criteria of efficiency, efficacy, and cost-effectiveness.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.